NCT02173171
- Conditions
- Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial, Melanoma, Neoplasms, +10 more
- Locations
-
- University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
- University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
- St Joseph Heritage Healthcare Santa Rosa, California, United States
- University of Colorado Cancer Center Aurora, Colorado, United States